Profluent raises $106M Series B co-led by Altimeter and Bezos Expeditions

Profluent

Profluent raised $106 million, bringing its total to $150 million, to scale its protein models and move beyond gene editing into antibodies, enzymes and other formats. The Emeryville, California company aims to put an AI-designed therapy into patients.

• Co-leads Altimeter Capital and Bezos Expeditions; Spark, Insight and Air Street also invested.
• Thousands of companies, labs and large pharma groups use OpenCRISPR-1, per the company.
• Partners include Revvity, Corteva, IDT and the Rett Syndrome Research Trust.